Abstract: Magnesium, the fourth most abundant cation in the human body, is involved in several essential physiological, biochemical, and cellular processes regulating cardiovascular function. It plays a critical role in modulating vascular smooth muscle tone, endothelial cell function, and myocardial excitability and is thus central to the pathogenesis of several cardiovascular disorders such as hypertension, atherosclerosis, coronary artery disease, congestive heart failure, and cardiac arrhythmias. This review discusses the vasodilatory, anti-inflammatory, anti-ischemic, and antiarrhythmic properties of magnesium and its current role in the prevention and treatment of cardiovascular disorders.
Hypertension is an important risk factor for endothelial damage/ dysfunction, an essential step in the pathogenesis of atherosclerosis, ultimately leading to CAD.
5 CAD, in turn, initiates a sequence of adverse cardiovascular events beginning with myocardial infarction (MI) followed by ischemic cardiomyopathy, heart failure, cardiac arrhythmias, and sudden cardiac death. Because Mg 2+ is crucial for the normal physiological functioning of vascular smooth muscle cells (VSMCs), endothelial cells, and myocardium, reduced Mg 2+ levels could represent a common link between these adverse cardiovascular events. Studies have shown that hypomagnesemia is indeed associated with increased cardiovascular morbidity and mortality. [6] [7] [8] [9] Therefore, evaluating the potential role of Mg 2+ in the diagnosis and treatment of cardiovascular disorders becomes imperative.
MAGNESIUM HOMEOSTASIS

Mg
2+ is widely distributed in plant and animal foods, in beverages, and in over-the-counter dietary supplements and vitamins. In general, foods containing dietary fiber provide Mg
2+
. For instance, green leafy vegetables, such as spinach, legumes, nuts, seeds, and whole grains are rich sources. Evidence suggests that the typical "American-type" diet is relatively deficient in Mg 2+ compared with the "Oriental" diet that is richer in Mg 2+ due to a greater intake of fruits and vegetables. 10 
Mg
2+ is the second most abundant intracellular cation and the fourth most abundant cation in the body (Ca 2+ > K + > Na + > Mg
2+
).
1
Approximately 65% of the total body Mg 2+ is in bone, approximately 34% in muscle, but 1% in plasma and interstitial fluid.
11 Both intraand extracellular Mg 2+ exist in 3 functional states: (1) free or ionized (the physiologically active form), (2) protein bound, and (3) complexed to anions (bicarbonate, phosphate, citrate, and lactate).
With regard to extracellular Mg
2+
, 60% is in the free or ionized form, 33% is protein bound (mostly to albumin), and 7% is complexed to anions. 12 Within cells, Mg 2+ is compartmentalized in the nuclei, mitochondria, and endo/sarcoplasmic reticulum. 13 Within these compartments, Mg 2+ binds to chromatin and nucleic acid, matrix adenine phosphonucleotides and intermembrane proteins, and ribonuclear proteins and phospholipids, respectively. 13, 14 As a result of this binding, only a small fraction of intracellular Mg 2+ exists in the free form. The total intracellular Mg 2+ concentration ranges between 14 and 20 nM, whereas the intracellular free Mg 2+ concentration is estimated to be about 0.5-0.7 nM.
15,16
Mg
2+ is a dynamic ion, the transcellular transport of which involves several efflux and influx systems. Mg 2+ efflux involves Na /anion cotransport, counter-transport pathways using the electrochemical gradient of Na + , and via cation channels. At least 7 transcellular Mg 2+ channels have been cloned, including the mitochondrial RNA splicing 2 protein, the human solute carrier family 41, members 1 and 2 (SLC41A1, SLC41A2) channels, magnesium transporter 1, ancient conserved domain protein 2, and transient receptor potential melastatin cation channels 6 and 7 (TRPM6, TRPM7). A paracellular Mg 2+ transporter, paracellin-1, has also been identified. [25] [26] [27] [28] [29] [30] Table 1 summarizes the tissue distribution, function, and the disease states associated with dysfunction of each of these transporters involved in Mg 2+ influx.
30-41
The above transport processes are intricately involved in the intestinal absorption of Mg 2+ and renal regulation of Mg 2+ excretion. Intestinal absorption of Mg 2+ proceeds in both a passive paracellular manner and an active transcellular manner. 42 
Paracellular absorption of Mg
2+ occurs mainly in the small intestine and is presumably mediated by claudin-16/paracellin-1. 43, 44 On the contrary, active transcellular absorption of Mg 2+ occurs almost exclusively in the colon and may involve Na 
/Mg
2+ antiport systems and the transcellular transporter TRPM6. Approximately 80% of total plasma Mg 2+ is filtered at the glomeruli, 15% of which is absorbed proximally, 70% in the thick ascending limb of the loop of Henle, and 15% in the distal convoluted tubule, with the remaining 3% to 5% excreted in the urine. The thick ascending limb is the main site of passive paracellular reabsorption of Mg
2+
, a process mediated by claudin-16 and -19. The distal convoluted tubule is the site for active transcellular reabsorption of Mg 2+ mediated via TRPM6. Mutation in TRPM6 is responsible for the rare monogenic disorder hypomagnesemia with secondary hypocalcemia in children who develop seizures and tetany due to extremely low Mg 2+ levels.
MAGNESIUM DEFICIENCY
The prevalence of hypomagnesemia in hospitalized patients has been estimated to be between 8% and 30%. 45 
49
MAGNESIUM AND VASCULAR SMOOTH MUSCLE CELLS
Clinical and experimental evidence suggests that Mg 2+ promotes vasodilation, reduces vascular resistance, and improves blood flow in systemic, coronary, cerebral, and renal circulations.
50-54 Both 
55,56
The screening of surface charges is more marked extracellularly than intracellularly probably due to an asymmetrical distribution of negatively charged sialic acid residues in the cell membrane. 81 In a double-blind controlled trial, Witteman et al 82 showed that the treatment of middleaged and elderly women with mild-to-moderate hypertension with oral magnesium aspartate-HCl for 6 months lowered systolic and diastolic blood pressures by 2.7 and 3.4 mm Hg, respectively. Several similar clinical trials have shown a modest reduction in both systolic and diastolic blood pressures in response to oral or intravenous Mg 2+ treatment in hypertensive patients. [83] [84] [85] However, other studies, such as the Trials of Hypertension Prevention, have failed to demonstrate a beneficial effect of Mg 2+ on lowering blood pressure in adults with hypertension. 86 A meta-analysis of 20 randomized clinical trials testing the effect of Mg 2+ supplementation on blood pressure revealed that Mg 2+ supplementation produced a dose-dependent but small overall reduction in blood pressure. 87 While Mg 2+ supplementation along with other alternative treatments such as vitamin C, coenzyme Q10, and omega-3 fatty acids has been suggested for the management of hypertension in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, evidence for its effectiveness is lacking from well-designed, randomized, controlled trials. 88 Therefore, long-term and better quality double-blind placebo-controlled trials in carefully characterized hypertensive patients are needed to make any definitive recommendations on the therapeutic use of supplemental Mg 2+ in the management of hypertension.
MAGNESIUM AND THE ENDOTHELIUM
Because endothelial cells are strategically located at the interface of blood and vessel wall, they play an important role not only in controlling VSM tone and blood flow but also in regulating vascular permeability, maintaining a nonthrombogenic environment, and influencing immune and inflammatory reactions. It is well accepted that endothelial dysfunction is central to the pathogenesis of atherosclerosis, thrombosis, hypertension, and diabetes. 89, 90 Besides modulating Ca 2+ entry, NO and PGI 2 production, Mg 2+ influences several other aspects of endothelial pathophysiology. Low Mg 2+ levels have been shown to inhibit endothelial proliferation and migration and upregulate the expression of interleukin-1, -6, vascular cell adhesion molecule, and plasminogen activator inhibitor-1, thereby producing a proinflammatory, prothrombotic, and proatherogenic environment. 91, 92 Recently, Dong et al 93 showed that MgSO 4 enhances the cleavage of the prothrombotic ultra-large von Willebrand factor by a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS-13) and significantly reduces von Willebrand factor-mediated platelet adhesion and aggregation on immobilized collagen, thus preventing the tendency to develop thrombosis. The role of reactive oxygen species and oxidized lowdensity lipoprotein (OxLDL) in the pathogenesis of atherosclerosis is well-established. 94 Experimental evidence exists, suggesting that Mg 2+ deficiency potentiates free radical production and oxidative stress in endothelial cells through reduction in plasma antioxidants and increased lipid peroxidation.
95-97 Au-Yeung et al 98 recently showed that magnesium tanshinoate B, a compound purified from a Chinese herb danshen (Salvia miltiorrhiza), significantly inhibits c-Jun N-terminal kinase activation, cytochrome c release, and caspase-3 activation induced by Cu-OxVLDL or Cu-OxLDL, resulting in a marked reduction in endothelial cell apoptosis, suggesting that Mg 2+ could have a potential therapeutic role in the prevention/treatment of atherosclerosis.
Several animal and human experiments also support the role of Mg 2+ in the pathogenesis and treatment of atherosclerosis and its complications. Sherer et al 99 showed that fortification of drinking water with MgSO 4 or MgCl 2 attenuates atherogenesis in both male and female LDL receptor-deficient mice fed high-cholesterol diet.
100
In addition, Ravn et al 101 showed that ApoE-deficient mice receiving a low-fat diet and fortification of drinking water with MgSO 4 significantly reduced the median plaque area, and cholesterol and triglyceride levels. Recently, in agreement with the above findings, it was demonstrated that rabbits with inadequate dietary intake of Mg 2+ developed more plaques and had higher total and non-high-density lipoprotein cholesterol and triglyceride levels than controls, suggesting that inadequate intake of Mg 2+ is an independent risk factor for atherosclerosis. 102 Because postprandial hyperlipidemia has been recognized to be a risk factor for atherosclerosis, Kishimoto et al 103 studied the effect of Mg 2+ supplementation on postprandial serum lipid levels. Serum and chylomicron triacylglycerol responses after the fat load were found to be reduced and delayed by Mg 2+ supplementation.
Also, the concentrations of apo-B48, remnant-like particle cholesterol, and nonesterified fatty acids were found to be significantly lower after the fat-with-Mg 2+ meal compared with the fat-only meal, suggesting that Mg 2+ supplementation inhibits fat absorption and improves postprandial hyperlipidemia. 
MAGNESIUM AND THE MYOCARDIUM
Anti-ischemic Effects
The cardioprotective effects of Mg 2+ are well-established. Several studies have shown that myocardial ischemia followed by reperfusion results in cytoplasmic Ca 2+ overload. 107, 108 Mg 2+ confers cellular protection during myocardial ischemia by (1) acting as a Ca 2+ antagonist, thereby reducing Ca 2+ overload, (2) conserving cellular adenosine triphosphatase (ATP) as the magnesium salt and thereby preserving energy-dependent cellular processes, (3) reducing myocardial oxygen consumption by lowering the heart rate, contractility, systemic afterload, and attenuating catecholamine-induced elevated oxygen demand, and (4) protecting the post-ischemic myocardium from oxidative damage. [109] [110] [111] [112] Based on these effects of Mg
2+
, it is not surprising that Mg 2+ therapy has been studied extensively in the context of acute MI. The Second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2) was the first randomized, double-blind, placebo-controlled study demonstrating the efficacy of intravenous magnesium therapy in reducing early mortality in acute MI.
113 Two thousand three hundred sixteen patients with suspected acute MI were randomized to receive either intravenous MgSO 4 or placebo. There was a 24% relative reduction in 28-day mortality and a 25% reduction in the incidence of left ventricular failure in the MgSO 4 group. The study concluded that intravenous MgSO 4 is a simple, safe, and widely applicable treatment for acute MI, and its efficacy in reducing early mortality is comparable with, but independent of, that of thrombolytic or antiplatelet therapy.
However, 2 subsequent mega-trials, ISIS-4 (Fourth International Study of Infarct Survival) and MAGIC (Magnesium in Coronaries), failed to demonstrate a beneficial effect of magnesium therapy in acute MI. 114, 115 In the ISIS-4 trial, 58,050 patients with suspected acute MI were randomized to receive oral captopril, oral controlled-release mononitrate, or intravenous MgSO 4 . The study showed increased 35-day mortality and increased incidence of cardiogenic shock and CHF in the MgSO 4 group. No benefit was observed in the treatment group across all major subgroups, whether they were treated early or late and whether they received thrombolysis. The MAGIC trial compared short-term mortality in 6213 patients with ST elevation MI who were randomized to receive either intravenous MgSO 4 or placebo. At 30 days, 15.3% patients in the magnesium group and 15.2% in the placebo group had died (odds ratio 1.0; 95% CI, 0.9-1.2, P = 0.96). No benefit or harm of magnesium was observed in subgroup analyses. Potential explanations for the conflicting results of these various trials could be differences in time to randomization from symptom onset which might have influenced the attainment of elevated serum Mg 2+ levels sufficient to prevent myocardial reperfusion injury and the increased use of aspirin, β-blockers, and angiotensin-converting enzyme inhibitors in the ISIS-4 and MAGIC study populations, which might have superseded the potential cardioprotective effects of Mg 2+ . A recent meta-analysis of all randomized controlled trials that compared intravenous magnesium with placebo in the presence or absence of thrombolytic therapy in addition to routine treatment in patients with acute MI concluded that (1) magnesium is unlikely to reduce mortality in patients treated early or late and in patients already receiving thrombolytic therapy; (2) magnesium is unlikely to reduce mortality when used at high dose (≥75 mmol); (3) magnesium may reduce the incidence of ventricular fibrillation, ventricular tachycardia, and severe arrhythmia needing treatment, but it may increase the incidence of hypotension, bradycardia, and flushing; and (4) the areas of uncertainty regarding the effect of magnesium on mortality remain the effect of low-dose treatment (<75 mmol) and its efficacy in patients not treated with thrombolytics. 116 Overall, in light of the current clinical evidence, there is no indication for the routine administration of intravenous magnesium in patients with acute MI. However, owing to the experimentally proven cardioprotective effects of Mg
, promising results from animal studies, relatively low cost, and ease of administration, together with its generally good tolerability, it could be worthwhile to re-evaluate the potential therapeutic role of Mg 2+ in acute MI in further clinical trials before this inexpensive therapy is entirely cast aside
Antiarrhythmic Effects
Probably the most widely accepted and practiced use of Mg , and K + channels in the generation of cardiac action potential and the pathogenesis of cardiac arrhythmias is well-established; however, very few studies have evaluated the effect of Mg 2+ on cardiac voltage-dependent Na + channels. Using inside-out patches from guinea pig ventricular myocytes to measure currents through single cardiac Na + channels, Mubagwa et al 62 showed that (Mg
2+
) i had no effect on inward currents but decreased the outward current amplitude in a concentration and voltage-dependent manner. 117 
118
The effects of Mg 2+ on L Ca amplitude are modulated by the state of phosphorylation of the L Ca . Phosphorylation via the protein kinase A-dependent pathway enhances the L Ca current amplitude and also enhances the inhibitory action of Mg 2+ . Conversely, dephosphorylation of the channels by either protein kinase inhibitors or phosphatases decreases the Mg 2+ effect. 118 The effect of Mg 2+ is not due to changes in cyclic adenosine monophosphate concentration or channel phosphorylation but appears to be a direct effect of Mg 2+ on the phosphorylated channel or on channel dephosphorylation. 120 Binding of Mg 2+ inhibits phosphorylated channels from undergoing the conformational changes that result in more frequent opening. Nonetheless, the ATP-bound form of Mg 2+ (Mg 2+ -ATP) is required for protein kinase A-or PKC-mediated L Ca phosphorylation.
(Mg
2+
) i and guanosine triphosphate (GTP) act synergistically to inhibit L Ca . GTP and other guanine di-or trinucleotides have been shown to inhibit L Ca channels in a G-protein-independent manner.
123
Both Mg
2+ and GTP can directly bind to L Ca , but because of different charges, Mg 2+ and GTP 2-have independent binding sites, with the binding of one allosterically preventing the binding of the other. Most L Ca bind Mg 2+ and/or GTP and remain in a nonavailable state under basal conditions. Depletion of (Mg
2+
) i relieves the Mg 2+ block because the blocking device in the C-terminal region of α-subunit of L Ca can no longer block the channel when free of Mg
. 124 However, in the presence of GTP, depletion of (Mg 2+ ) i allows GTP to bind to L Ca , thereby allowing it to exert its inhibitory effect, thus maintaining the channels in a nonavailable state.
Besides voltage-dependent Na + and L Ca channels, Mg 2+ can also influence the inward and delayed rectifier K + channels expressed in cardiac cell membrane. The inward rectifier K + channels (I K1 ) are highly expressed in atrial and ventricular contractile cells, and in ventricular conduction cells, but less expressed in nodal cells.
62
I K1 current is the primary determinant of resting membrane potential of cardiac cells. It is well-established that the strong inward rectification results from voltage-dependent block by intracellular organic cations called polyamines. 125 Although the polyamines spermine and spermidine are the most potent inducers of inward rectification, (Mg 2+ ) i also plays an important role. 126 Furthermore, this strong voltage-dependent rectification is influenced by extracellular K + such that elevated extracellular K + levels relieve the polyamine-or Mg 2+ -induced rectification. 127 The delayed rectifier K + (I K ) current, composed of rapidly activating (I Kr ) and slowly activating (I Ks ) components mediated by 2 different channel proteins, HERG and K v LQT1, respectively, is critical for the repolarization phase of cardiac action potential.
128,129 Elevated (Mg
2+
) i in mammalian cardiac myocytes decreases I K current, whereas decreased (Mg 2+ ) i produces the opposite effect. 130 A small increase in (Mg
) i in the physiological range from 0.3 to 1.0 mM suppresses the current by 50-60%. Because this effect is observed in both nonstimulated cells and cyclic adenosine monophosphate-treated cells, it has been speculated that these modulatory effects of (Mg 2+ ) i on I K are independent of channel phosphorylation. 131 Lastly, because voltage-independent modulation of both outward and inward current through I K occurs, the (Mg
) i modulation of these channels does not appear to result from the open channel blocking effect observed on the I K1 channels. Rather, it has been suggested that the I K channels express a binding site for (Mg
) i , which may modulate the availability or opening of these channels.
124
Based on the physiological effects of Mg 2+ on cardiac ion channels, it is obvious that Mg 2+ influences cardiac impulse formation and conduction and thereby plays a critical role in the pathogenesis and treatment of cardiac arrhythmias. A recent study of 3530 participants from the Framingham Offspring Study showed that low serum Mg 2+ is moderately associated with the development of atrial fibrillation (AF) in individuals without CVD. 132 The use of intravenous Mg 2+ in the prevention and treatment of cardiac arrhythmias has been reviewed recently.
133 Some of the important points together with data from some recent clinical trials will be discussed here. Table 3 summarizes the electrophysiological effects of Mg 2+ on the supraventricular and ventricular conduction pathways.
134-142
New-onset AF, atrial flutter (AFL), and other atrial tachyarrhythmias occur in 15-50% of patients after cardiac surgery and are associated with increased risk of CHF and stroke, prolonged hospitalization, and increased costs. [143] [144] [145] Based on a meta-analysis of randomized, controlled clinical trials (1979 to 2001), the American College of Chest Physicians (ACCP) recommends the use of β-blockers (Vaughn-Williams Class II antiarrhythmic agents) as the first choice for prophylaxis against postcardiac surgery AF, even in patients receiving long-term therapy with β-blockers prior to surgery. 146 Because only 1 of 14 trials evaluating the potential benefit of MgCl 2 or MgSO 4 in reducing postcardiac surgery AF showed a statistically significant reduction, the ACCP has recommended against the routine use of magnesium for the prevention of AF/AFL following cardiac surgery.
146 However, the 13 trials that produced inconclusive results had several limitations, including postoperative β-blocker withdrawal in some patients and methodological weaknesses, thus making the overall quality of opposing evidence low. The ACCP does recommend that in patients undergoing cardiac surgery, serum Mg 2+ levels should be maintained within the normal range, perhaps with empiric supplementation, especially because hypomagnesemia has been shown to exacerbate the proarrhythmogenic effect of hypokalemia, another common occurrence in the patient having undergone cardiac surgery.
147
Several other meta-analyses have shown that intravenous magnesium is indeed an effective and safe strategy for prophylaxis against postcardiac surgery AF and for acute management of rapid AF. [148] [149] [150] Vaughn-Williams Class III antiarrhythmic agents such as sotalol, amiodarone, ibutilide, and dofetilide are considered the second-line drugs for prophylaxis against postcardiac surgery AF/AFL 2+ has been shown to cause a significant decrease in the number of ventricular ectopic beats, couplets, and episodes of nonsustained ventricular tachycardia in patients with New York Heart Association class II-IV heart failure. 167, 168 Ventricular arrhythmias are common following coronary artery bypass grafting, and their occurrence coincides with the postoperative decline in serum Mg 2+ levels. Parikka et al 169 showed that correction of the postoperative decline in serum Mg
2+
concentration decreases the occurrence of early ventricular premature complexes and complex ventricular arrhythmias in coronary artery bypass surgery patients, and the benefit appears to be the greatest in patients with extensive underlying CAD and prior diuretic therapy. Lastly, data from the Magnesium in Cardiac Arrhythmias (MAGICA) trial showed a significant reduction in ventricular premature beats in patients with frequent ventricular arrhythmias (>720 beats/24 h) following a 50% increase in the minimum daily dietary intake of Mg
and K + for 3 weeks, further emphasizing the beneficial effects of Mg
in the management of ventricular arrhythmias.
170
MAGNESIUM SUPPLEMENTATION
Prior studies suggest that oral Mg 2+ supplementation is inexpensive, relatively safe, and well tolerated. 171 abolishes EADs and triggered automaticity, thereby terminating the arrhythmia. Adapted with permission from Yap and Camm. 160 Adaptations are themselves works protected by copyright. So in order to publish this adaptation, authorization must be obtained both from the owner of the copyright in the original work and from the owner of copyright in the translation or adaptation.
CONCLUSIONS
Mg
2+ has vasodilatory, anti-inflammatory, anti-ischemic, and antiarrhythmic properties (Fig. 3) . It is a critically important nutrient and a potentially useful therapeutic agent in cardiovascular medicine. Several experimental, epidemiological, and clinical studies have established the role of Mg 2+ in the pathogenesis of cardiovascular disorders. Currently, the use of Mg 2+ is limited mostly for the prevention and/or treatment of cardiac arrhythmias. We believe that adequate Mg 2+ intake should be a part of the heart healthy diet. However, there is a compelling need for several well-designed cohort studies to determine the interrelationship among dietary Mg 2+ intake, serum (or intracellular) Mg 2+ concentration, and CVD, and to provide concrete evidence on the risks and/or benefits of taking Mg 2+ supplements. Future basic science research should be focused on gaining a better understanding of the metabolic effects of Mg 2+ intake in health and disease. Lastly, larger well-designed, randomized controlled trials are needed to widen the therapeutic scope of this inexpensive nutrient. ) on vascular smooth muscle cells (VSMC), endothelium and heart. AV indicates atrioventricular; IL-1, interleukin-1; IL-6, interleukin-6; MVO 2 , myocardial oxygen consumption; NO, nitric oxide; PAI1, plasminogen activator inhibitor-1; PGI 2 , prostacyclin; PVR, peripheral vascular resistance; VCAM-1, vascular cell adhesion molecule-1.
